PT - JOURNAL ARTICLE AU - Neil A Caldwell AU - Ceri Townsend TI - Where are we with RSV prophylaxis? AID - 10.1136/archdischild-2015-308780 DP - 2016 Feb 01 TA - Archives of disease in childhood - Education & practice edition PG - 38--42 VI - 101 IP - 1 4099 - http://ep.bmj.com/content/101/1/38.short 4100 - http://ep.bmj.com/content/101/1/38.full SO - Arch Dis Child Educ Pract Ed2016 Feb 01; 101 AB - Respiratory syncytial virus (RSV) is a predictable, seasonal disease with significant morbidity and mortality in children below 24 months. Prophylaxis, which decreases hospitalisation in those most vulnerable to the disease, has been available since 1998. Pharmacological prophylaxis is however, expensive and requires good infrastructure to deliver. It is out of reach for many patients in low-income and middle-income countries where mortality is highest. This article looks at the pathophysiology and risk factors for RSV. It also outlines what agents are currently available for prophylaxis and prevention.